# Junta clínica — PT-pseudo_cac2563c222a (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_cac2563c222a",
  "pid": "PT-pseudo_cac2563c222a",
  "task": 1,
  "psa": 4.53,
  "age": 50,
  "months": 3,
  "pirads": "5",
  "psad": 0.12,
  "psav": 0.54,
  "psap": 4.1,
  "vol": 41.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.84312165,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.53 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 41 mL. csPCa 0.84.",
  "pmhx": [],
  "allergies": [
    "NSAIDs"
  ],
  "vitals": {
    "weight": "86 kg",
    "height": "182 cm",
    "bmi": "26.0",
    "bp": "143/64 mmHg",
    "hr": "64 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested to review a previous prostate biopsy alongside a steadily climbing PSA curve."
    },
    {
      "s": "History",
      "t": "A 50-year-old freelance translator residing with his wife came under scrutiny after a PSA elevation emerged in mid-2023. He denies any lower urinary tract complaints, recording an IPSS of 1 out of 35, and reports no pelvic discomfort or blood in the urine. A non-smoker, he drinks roughly 26 alcoholic units each week and stays physically active through weekend hiking excursions. Unrelated recent visits included a dermatology check for actinic keratosis monitoring and a routine flu shot given by the practice nurse. He has never undergone major operations, uses no daily prescriptions, and handles remote work using enlarged print because of mild vision loss. Despite some mild worry about the PSA curve, he feels otherwise healthy. The prior biopsy bucket is Positive."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetrically normal; mobility: unrestricted; asymmetry: absent. General inspection shows stable vital signs, clear peripheral lymph nodes, and no skeletal tenderness. Abdominal palpation confirms a soft, non-tender cavity devoid of masses."
    }
  ],
  "occupation": "freelance translator",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "26 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_cac2563c222a
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 50-year-old male
  - PSA: 4.53 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.54 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84312165 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NSAIDs
  - Additional notes: PSA 4.53 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 41 mL. csPCa 0.84.

Vitals: weight 86 kg, height 182 cm, BMI 26.0, BP 143/64 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested to review a previous prostate biopsy alongside a steadily climbing PSA curve.

History: A 50-year-old freelance translator residing with his wife came under scrutiny after a PSA elevation emerged in mid-2023. He denies any lower urinary tract complaints, recording an IPSS of 1 out of 35, and reports no pelvic discomfort or blood in the urine. A non-smoker, he drinks roughly 26 alcoholic units each week and stays physically active through weekend hiking excursions. Unrelated recent visits included a dermatology check for actinic keratosis monitoring and a routine flu shot given by the practice nurse. He has never undergone major operations, uses no daily prescriptions, and handles remote work using enlarged print because of mild vision loss. Despite some mild worry about the PSA curve, he feels otherwise healthy. The prior biopsy bucket is Positive.

Physical examination: DRE — texture: smooth and symmetrically normal; mobility: unrestricted; asymmetry: absent. General inspection shows stable vital signs, clear peripheral lymph nodes, and no skeletal tenderness. Abdominal palpation confirms a soft, non-tender cavity devoid of masses.

Patient info: freelance translator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 26 units / week; exercise Hiking on weekends; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; GP practice nurse — flu vaccination.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.11 epistemic (95% band 0.43-0.86); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  2. distance 1.69: PI-RADS 5, PSA 8.7, PSAD 0.4, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Young patient with high risk disease, should be recommended curative treatment. Biopsy report congruent with MRI, probably caught the index cancer at diagnosis. Highrisk…"
  3. distance 2.03: PI-RADS 4, PSA 9.0, PSAD 0.16, age 52, DRE Normal -> BIOPSY (borderline). He wrote: "I need information on initial ISUP and size of P4 lesion in initial scan."

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: psa=important, age=important, psad=important, cspca=important, dre=noted, pirads=important, vol=noted, bx=important, fh=noted, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings, which are not yet fully established. The precedent cited by Expert 1 is not decisive because the guideline makes the decision dependent on the documented grade of the prior biopsy and the surveillance history, which is what the Registrar is tasked to find.

WHAT WE STILL NEED
The panel already provides the prior biopsy status as "Positive," which is a fact that the guideline makes decisive.
The prior biopsy status is "Positive," which dictates the next step based on the guideline.
The documented grade of the prior biopsy and the number and dates of biopsy sessions in the notes are needed to determine the next step.
Whether the patient is on a surveillance protocol with a confirmatory biopsy due is needed to determine the next step.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and surveillance status from the previous notes, as the guideline requires this information to determine the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling) beyond the headline value?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of biopsies, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and hemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. How many biopsy sessions were performed and when were they conducted?
  Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
The report states: "Total gland volume registers at 41.0 mL. T2-weighted sequences highlight a sharply demarcated hypointense area within the right peripheral zone at the mid-gland level, spanning roughly 12 mm. No extracapsular extension or seminal vesicle invasion is evident."

psa_trend
What is the serial PSA value trend (rising, flat, or falling) beyond the headline value?
The serial PSA value trend is rising, with values: "Jun 2023: 3.3", "Jan 2024: 3.7", "Aug 2024: 4.1", and "Feb 2025: 4.53".

previous_notes
What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of biopsies, and surveillance protocol status?
The management context includes: "Initial laboratory screening in late 2022 recorded a PSA level of 3.2 ng/mL, which climbed to 3.4 ng/mL by June 2023. Because of this upward trend, a urology referral was initiated to arrange further assessment and book the initial biopsy." and "Post-consultation update indicates the earlier biopsy established Gleason 3+3 disease. The current PSA measures 3.5 ng/mL. Clinical notes document the ongoing surveillance plan."

laboratory_results
What are the full panel results, including free-PSA fraction, renal function, and hemoglobin?
The full panel results include: "PSA: 4.5 ng/mL" on "13 Feb 2025", "Free PSA: 1.10 ng/mL" on "13 Feb 2025", "%Free PSA: 24%" on "13 Feb 2025", "Haemoglobin: 14.0 g/dL" on "13 Feb 2025", "Creatinine: 98 umol/L" on "13 Feb 2025", and "eGFR: >60 mL/min/1.73m2" on "13 Feb 2025".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the relevant biopsy grade and surveillance context needed for the decision.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the right mid-peripheral zone.
Serial PSA value trend is rising.

Findings that argue AGAINST sampling this patient now:
Prior biopsy established Gleason 3+3 disease.
The patient is documented as being on an ongoing surveillance plan.

WHERE THIS LEANS
The findings suggest a high-risk scenario based on the MRI and PSA trend, but the prior biopsy result and surveillance status are the critical missing pieces required by the guideline.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 4.53 ng/mL over 4 points spanning 20 months; velocity +0.73 ng/mL per year; doubling time about 44 months.
PROJECTION at 6 months: 5.0 ng/mL, conformal 95% band 1.4-17.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.70
  uncertainty  +/- 0.11 epistemic (95% band 0.48-0.92), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.65  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.70  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)

  documented prior grade in the opened documents: GG 1 ("Gleason 3+3")

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: psa=important, age=important, psad=important, cspca=important, dre=noted, pirads=important, vol=noted, bx=important, fh=noted, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—address all three moderator questions. The previous_notes explicitly state the prior biopsy established Gleason 3+3 disease, which answers Q1. The previous_notes also mention an "ongoing surveillance plan," which addresses Q3. The number of biopsy sessions (Q2) is not explicitly stated in the retrieved notes, but the context of an "ongoing surveillance plan" implies prior biopsies have occurred.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the protocol fired based on the EXPERT-LIBRARY precedent, which is supported by the retrieved finding that the documented prior grade is "GG 1 ('Gleason 3+3')".

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? Answered by previous_notes: Gleason 3+3 disease.
Q2. How many biopsy sessions were performed and when were they conducted? This information is not explicitly retrieved from the opened documents.
Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by previous_notes: Clinical notes document the ongoing surveillance plan.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 3+3) is highly relevant because it is a critical factor in determining the next step, as highlighted by the EAU guideline specialist. The rising PSA trend and the PI-RADS 5 finding also weigh heavily toward further investigation.

MY SUGGESTION TO THE CHAIR
Given that the panel protocol is based on a precedent, and the retrieved information confirms a high-risk scenario (Gleason 3+3 and rising PSA), the recommendation should be to proceed with a biopsy to confirm histological progression, as suggested by the panel.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the documented prior biopsy established Gleason 3+3 disease and the patient is on an ongoing surveillance plan, a confirmatory biopsy is indicated per guideline requirements. This decision is supported by the high-risk features, specifically the PI-RADS 5 lesion and the rising PSA trend, which converged with the panel protocol's reliance on the identical precedent. The evidence converged to recommend proceeding with a biopsy to confirm histological progression.

What carried weight: psa=important, age=important, psad=important, cspca=important, dre=noted, pirads=important, vol=noted, bx=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
